- Oramed Pharmaceuticals Inc. is **independently advancing its oral insulin program** with a new 60-patient U.S. trial, following the termination of its joint venture with Hefei Tianhui Biotech Co. Ltd..  **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:0]** **[1176309_0001213900-25-101825_ea0262319-8k_oramed.htm:2]** 
- The company's diversified investment portfolio has yielded substantial returns, including a **$27.1 million gain** on its Alpha Tau Medical Ltd. investment and **$95.5 million returned** from a loan to Scilex Holdings.  **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:0]** **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:1]** 
- Total cash and assets increased to approximately **$210 million** as of September 30, 2025 (unaudited), from $155.7 million in January 2023, while also investing **$17.8 million** in R&D and share buybacks.  **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:2]** 
- Oramed repurchased **1,155,367 shares** for **$2,576,468.41** on October 20, 2025, and reaffirms plans for a **one-time dividend** to shareholders.  **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:0]** **[1176309_0001213900-25-101825_ea026231901ex10-1_oramed.htm:0]** **[1176309_0001213900-25-101825_ea0262319-8k_oramed.htm:1]** **[1176309_0001213900-25-101825_ea026231901ex99-1_oramed.htm:2]**

ORAMED PHARMACEUTICALS (ORMP)